Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution -- Expected to be accretive to 2023 earnings

Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution

-- Expected to be accretive to 2023 earnings --

PARK, Illinois - September 13, 2022 - Eton Pharmaceuticals ("Eton" or "the Company") (Nasdaq: ETON),

an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the acquisition

of betaine anhydrous for oral solution.

are excited to add another FDA-approved rare disease product to our growing metabolic genetics portfolio. Betaine shares the same prescriber

base as our carglumic acid tablets, so it is an attractive opportunity to leverage our existing commercial infrastructure.

We plan to integrate the product later this year and expect the transaction to be accretive to 2023

earnings," said Sean Brynjelsen, CEO of Eton Pharmaceuticals. "This acquisition allows us to further advance

our mission of commercializing products for small, underserved orphan populations, and we will continue to seek out attractive late-stage

rare disease products to expand our portfolio."

anhydrous for oral solution targets a population of fewer than 2,000 patients in the United States, with an estimated market of $10 million

Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. is an innovative pharmaceutical

company focused on developing, acquiring, and commercializing treatments for rare diseases. The Company currently commercializes ALKINDI

SPRINKLE and Carglumic Acid tablets and has four additional rare disease products under development, including dehydrated

alcohol injection and the ZENEO hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

M. Wilson, In-Site Communications, Inc.

Eton Pharmaceuticals